Skip to content

Clinical trials

Observational Macular Degeneration trials

Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.

Filters: Condition: Macular Degeneration Phase: Observational Clear all

350 trials match Source: ClinicalTrials.gov registrations

Trials started per year

By phase, 2000 to 2026.

Trials started per year
CategoryTrials
20004
20021
20034
20041
20055
20068
200711
200821
200915
201011
20116
201225
201316
201415
201522
20167
201716
201812
201921
202023
202115
202216
202318
202412
202529
20269

Status

Trials by registry status. Select a bar to filter.

Trials by status
CategoryTrials
Completed196
Unknown status47
Recruiting39
Terminated23
Active, not recruiting17
Not yet recruiting15
Withdrawn7
Enrolling by invitation6

Top lead sponsors

A sponsor with a page on Pharma Observatory links to it.

Top lead sponsors
CategoryTrials
National Eye Institute (NEI)26
Notal Vision Ltd.20
Bayer15
Novartis Pharmaceuticals10
Medical University of Vienna8
Association for Innovation and Biomedical Research on Light and Image7
Pfizer6
Duke University5
Fondation Ophtalmologique Adolphe de Rothschild5
Insel Gruppe AG, University Hospital Bern5

Top conditions

MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.

Top conditions
CategoryTrials
Macular Degeneration350
Diabetic Retinopathy47
Choroidal Neovascularization25
Geographic Atrophy25
Glaucoma23
Retinal Vein Occlusion22
Retinal Diseases20
Cataract13
Macular Edema13
Retinitis Pigmentosa11

Trials

Showing 76 to 100 of 350. Each trial links to its page on Pharma Observatory.

250 more trials match. See them on Pharma Observatory

Recently changed trials

Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.

No changes to these trials in the last 7 days.

Go deeper on Pharma Observatory

Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.